Kiniksa Pharmaceuticals International (KNSA) EBIAT (2021 - 2025)
Historic EBIAT for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $18.4 million.
- Kiniksa Pharmaceuticals International's EBIAT rose 24523.75% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 49609.62%. This contributed to the annual value of -$43.2 million for FY2024, which is 40668.13% down from last year.
- Per Kiniksa Pharmaceuticals International's latest filing, its EBIAT stood at $18.4 million for Q3 2025, which was up 24523.75% from $17.8 million recorded in Q2 2025.
- In the past 5 years, Kiniksa Pharmaceuticals International's EBIAT ranged from a high of $224.1 million in Q3 2022 and a low of -$49.5 million during Q1 2021
- Moreover, its 5-year median value for EBIAT was -$12.3 million (2023), whereas its average is $2.2 million.
- As far as peak fluctuations go, Kiniksa Pharmaceuticals International's EBIAT soared by 83367.27% in 2022, and later tumbled by 13521.81% in 2024.
- Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's EBIAT stood at -$36.3 million in 2021, then surged by 112.28% to $4.5 million in 2022, then skyrocketed by 465.73% to $25.2 million in 2023, then crashed by 135.22% to -$8.9 million in 2024, then soared by 307.41% to $18.4 million in 2025.
- Its EBIAT stands at $18.4 million for Q3 2025, versus $17.8 million for Q2 2025 and $8.5 million for Q1 2025.